日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

伊沙妥昔单抗、卡非佐米和地塞米松治疗复发性多发性骨髓瘤患者：IKEMA（一项随机3期研究）的最新结果

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-023-00797-8
Martin, Thomas; Dimopoulos, Meletios-Athanasios; Mikhael, Joseph; Yong, Kwee; Capra, Marcelo; Facon, Thierry; Hajek, Roman; Špička, Ivan; Baker, Ross; Kim, Kihyun; Martinez, Gracia; Min, Chang-Ki; Pour, Ludek; Leleu, Xavier; Oriol, Albert; Koh, Youngil; Suzuki, Kenshi; Casca, France; Macé, Sandrine; Risse, Marie-Laure; Moreau, Philippe
多发性骨髓瘤
骨髓瘤
发表日期：2023
文献求助 收藏

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

更正：伊沙妥昔单抗、卡非佐米和地塞米松治疗复发性多发性骨髓瘤患者：IKEMA（一项随机3期研究）的最新结果

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/s41408-023-00923-6
Martin, Thomas; Dimopoulos, Meletios-Athanasios; Mikhael, Joseph; Yong, Kwee; Capra, Marcelo; Facon, Thierry; Hajek, Roman; Špička, Ivan; Baker, Ross; Kim, Kihyun; Martinez, Gracia; Min, Chang-Ki; Pour, Ludek; Leleu, Xavier; Oriol, Albert; Koh, Youngil; Suzuki, Kenshi; Casca, France; Macé, Sandrine; Risse, Marie-Laure; Moreau, Philippe
多发性骨髓瘤
骨髓瘤
发表日期：2023
文献求助 收藏

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA

根据 1q21+ 状态对接受 isatuximab 治疗的复发/难治性多发性骨髓瘤患者的主要结局进行分析：来自 ICARIA-MM 和 IKEMA 的亚组分析

期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2022.280660
Martin, Tom; Richardson, Paul G; Facon, Thierry; Moreau, Philippe; Perrot, Aurore; Spicka, Ivan; Bisht, Kamlesh; Inchauspé, Marlene; Casca, France; Macé, Sandrine; Van de Velde, Helgi; Suzuki, Kenshi
多发性骨髓瘤
骨髓瘤
发表日期：2022
文献求助 收藏